News | March 17, 2009

Cetero Research, Cardiocore Create Alliance for Clinic, Core Lab for Safety Trials

March 17, 2009 - Clinical pharmacology company Cetero Research and centralized cardiac testing company Cardiocore announced today a global strategic alliance to optimize the design, conduct and reporting of cardiac safety studies.

The alliance provides clinical trial sponsors direct access to the world’s most experienced team of Thorough QT (TQT) scientists, unparalleled subject enrollment and bed capacity, integrated study management and accelerated data delivery, the companies said. The partnership’s turnkey offering also streamlines sponsors’ vendor selection, quality evaluation and contracting processes.

“When selecting a clinic and core lab for cardiac safety trials, customers consistently tell us their most important needs are hands-on experts, top-quality facilities and seamless project controls,” said Dr. Jerry Merritt, CEO of Cetero Research. “By creating the first true integration between a top clinical pharmacology CRO and a top core lab, the Cetero-Cardiocore alliance is able to provide clients with a turnkey solution to their cardiac safety needs, with one contract, one project manager, and one final report.”

Cardioscore said its solution has a fully integrated study design, clinical conduct, project oversight, data interpretation and expert reporting.

Cetero and Cardiocore have validated the success of their unified service delivery through the joint conduct of TQT and other cardiac safety studies performed since the publication of the E-14 Guidance for Industry. Together, the two organizations offer unmatched expertise in clinical pharmacology, bioanalytical services, cardiac safety consulting, and electrocardiographic analyses. Their client base includes large multinational pharmaceutical companies, mid-tier specialty drug developers and emerging biotechnology firms.

For more information: www.cetero.com, www.cardiocore.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init